Adverse obstetric and perinatal outcomes following treatment of adolescent and young adult cancer: A population-based cohort study by Haggar, F. et al.
RESEARCH ARTICLE
Adverse Obstetric and Perinatal Outcomes
following Treatment of Adolescent and
Young Adult Cancer: A Population-Based
Cohort Study
Fatima A. Haggar1,2*, Gavin Pereira3,4, David Preen2, C. D’Arcy Holman2,
Kristjana Einarsdottir3
1. The Department of Surgery, The Ottawa Hospital Research Institute, The University of Ottawa, Ottawa,
Canada, 2. Centre for Health Services Research, School of Population Health, The University of Western
Australia, Perth, Australia, 3. Telethon Kids Institute, The University of Western Australia, Subiaco, Australia,
4. Center for Perinatal Pediatric and Environmental Epidemiology, School of Medicine, Yale University, New
Haven, Connecticut, United States of America
*fhaggar@toh.on.ca
Abstract
Objective: To investigate obstetric and perinatal outcomes among female survivors
of adolescent and young adult (AYA) cancers and their offspring.
Methods: Using multivariate analysis of statewide linked data, outcomes of all first
completed pregnancies (n51894) in female survivors of AYA cancer diagnosed in
Western Australia during the period 1982–2007 were compared with those among
females with no cancer history. Comparison pregnancies were matched by
maternal age-group, parity and year of delivery.
Results: Compared with the non-cancer group, female survivors of AYA cancer
had an increased risk of threatened abortion (adjusted relative risk 2.09, 95%
confidence interval 1.51–2.74), gestational diabetes (2.65, 2.08–3.57), pre-
eclampsia (1.32, 1.04–1.87), post-partum hemorrhage (2.83, 1.92–4.67), cesarean
delivery (2.62, 2.22–3.04), and maternal postpartum hospitalization.5 days (3.01,
1.72–5.58), but no excess risk of threatened preterm delivery, antepartum
hemorrhage, premature rupture of membranes, failure of labor to progress or
retained placenta. Their offspring had an increased risk of premature birth (,37
weeks: 1.68, 1.21–2.08), low birth weight (,2500 g: 1.51, 1.23–2.12), fetal growth
restriction (3.27, 2.45–4.56), and neonatal distress indicated by low Apgar score
(,7) at 1 minute (2.83, 2.28–3.56), need for resuscitation (1.66, 1.27–2.19) or
special care nursery admission (1.44, 1.13–1.78). Congenital abnormalities and
perinatal deaths (intrauterine or #7 days of birth) were not increased among
offspring of survivors.
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Conclusion: Female survivors of AYA cancer have moderate excess risks of
adverse obstetric and perinatal outcomes arising from subsequent pregnancies that
may require additional surveillance or intervention.
Background
In general, cancers that commonly occur among adolescents and young adults
(AYAs), ages 15–39 years, have a relatively good prognosis [1–3]. For several of
these malignancies (e.g., melanoma, Hodgkin’s lymphoma, thyroid and testicular
cancers), 5-year relative survival is in excess of 85% [1]. Recent improvements in
therapy and early detection of other common AYA malignancies, such as
carcinomas of the breast and cervix, have the potential to further increase overall
cancer survival in this age group [4, 5]. These advances will inevitably lead to
increases in the number of cancer survivors, who will potentially be faced with late
and long-term physical morbidity, as well as psychological and psychosocial
challenges [4, 6]. Female survivors considering pregnancy are faced with further
concerns about the impact of cancer therapy on their ability to maintain normal
pregnancy and the possibility of adverse outcomes among their offspring [7].
These effects may be manifested as an increase in obstetric complications or an
increase in the frequency of adverse neonatal outcomes, such as low birth weight,
small for gestational age and congenital malformations. In light of the recent trend
of delayed childbearing for personal, educational or professional reasons [8, 9],
evaluating the risks of pregnancy outcomes following treatment for cancer is of
increasing importance. Several institutions have reported their experience with
long-term survivors of diverse types of pediatric cancer [10–20]. However, there is
a paucity of studies focusing specifically on patients of childbearing age at the time
of cancer diagnosis. This population-based study investigated the occurrence of
selected adverse pregnancy and neonatal outcomes respectively, among females
diagnosed with cancer when aged 15–39 years and their offspring.
Methods
Health datasets
The Western Australian Data Linkage System (WADLS) was used to extract health
records of all females diagnosed with cancer in Western Australia (WA) during
the period 1st January 1982 to 31st December 2007, as well as a sample of females
without any cancer history. The WADLS is a comprehensive system linking
population-based health and related data from several statutory datasets through
probabilistic matching of routinely collected records from the same individual,
with the proportion of valid links estimated through audits and validity studies to
be.98.5% of matches [21]. The WA Cancer Registry (WACR), for which
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notification has been a statutory requirement since 1981 [22], was used to extract
patients’ basic demographic data, information on their tumor (date of diagnosis,
anatomic site, histologic type). Tumors were classified by histologic type as
described in the 3rd edition of the International Classification of Diseases for
Oncology [23], then grouped according to the Surveillance, Epidemiology, and
End Results Program (SEER) AYA cancer diagnostic classification, a scheme
developed to better define the major cancers that affect individuals between 15
and 39 years of age [24]. Tumors were further categorized by anatomic primary
site as those arising in the (i) abdomen (ii) pelvis, or (iii) all other tumors.
Exposure to cancer therapy was classified into one of five mutually exclusive
treatment groups: surgery alone, chemotherapy alone, radiation therapy alone,
chemotherapy plus radiation, and all other types and combinations of therapy.
The Midwives Notification System (MNS) was used to obtain patients basic
demographics and information on the pregnancy and delivery related to live
births and stillbirths (20 weeks or more gestation or birth weight $400 g) in WA,
1982–2007. Information collected included maternal characteristics (age at
delivery, marital status, ethnicity), pre-existing and new-onset health problems
during the pregnancy, obstetric procedures and outcomes, and perinatal
outcomes. The date of birth or pregnancy termination is registered with
measurements of the newborn such as weight, length and vital status. The
Hospital Morbidity Database System (HMDS), which lists principal and
additional diagnoses and procedures, coded according to the International
Classification of Diseases (ICD) editions 9 and 10, was used to extract data for all
hospital admissions.
Location and assignment of indices of socio-economic status
Socio-economic disadvantage was measured using Index of Relative Socio-
economic Disadvantage (IRSD), which is based on census data of prevalence of
low income, low educational attainment, high unemployment, rented dwellings,
one parent families, and lacking fluency in English and other measures of social
disadvantage [25]. The IRSD corresponded to the census collection district (CD)
of the maternal residential address. Each CD contains approximately 200
dwellings.
Selection of cases and comparison females
Cases were defined as females first diagnosed with histologically confirmed
malignancy in WA while aged 15–39 years, in the period January 1, 1982 and Dec
31, 2007, and who had a subsequent delivery, either live or still birth, in WA on or
before Dec 31, 2008. Only the first completed pregnancy ($20 weeks) following
cancer diagnosis was included. We created a frequency-matched comparison
cohort using completed pregnancies of women with no registered history of
cancer on the basis of maternal age (one year either way), delivery year (within 1
year), parity, and Aboriginal status. Any individual with a cancer diagnosis
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(primary or secondary) prior to their delivery was excluded from the comparison
group.
Adverse outcomes and exposure groups
Data on the obstetric and perinatal outcomes were obtained from the MNS based
on diagnosis by the attending clinician/midwife. Adverse obstetric outcomes
included the following: threatened abortion, threatened preterm labor, preterm
delivery (gestation ,37 weeks); preeclampsia (the onset of hypertension, i.e.,
systolic blood pressure.5140 mm Hg and/or diastolic blood pressure.590 mm
Hg from 20 weeks’ gestation onwards accompanied by proteinuria); antepartum
hemorrhage (defined as occurrence of placental abruption, placenta previa, or
other excessive bleeding during labor and delivery); pre-labor rupture of
membranes (PRoM: rupture of the membranes.12 h before onset of labor
irrespective of gestation at the time of membrane rupture); gestational diabetes
(diabetes first diagnosed during pregnancy, as confirmed by clinical investigations
e.g., glucose tolerance test); other adverse pregnancy outcomes (e.g., intrauterine
growth restriction (IUGR); intrauterine death (fetal death at $20 weeks of
gestation), postpartum hemorrhage (.5500 ml); Cesarean delivery. Adverse
perinatal outcomes included: low birth weight (less than 2,500 g), low 1-min
Apgar score (less ,7), resuscitation (defined as the need for endotracheal
intubation or external cardiac massage); admission to a special care unit; neonatal
death (infant death during the 1st week of life); and congenital abnormalities
identified prior to discharge from hospital.
Statistical Analysis
Initial descriptive analysis followed by univariate analysis of study factors using
Chi squared (x2) testing was performed. Stratified Mantel-Haenszel methods were
applied to estimate relative risk (RR) with 95% confidence intervals (CI. The
results were similar to those produced by log-binomial or Poisson models [26].
All models were adjusted for frequency-matched variables (parity, year of delivery,
maternal age-group). Other variables used for adjustments were aboriginal status,
residential remoteness, hospital insurance status, previous cesarean section, use of
fertility treatment and maternal smoking during pregnancy. Gestational age was
adjusted for in LBW. Sub-analyses were conducted, stratified by age at diagnosis,
cancer SEER diagnostic groups, cancer anatomic site, calendar-period of




A total of 1894 females were diagnosed with cancer in WA between 1982 and 2007
(Table 1). The majority of females were diagnosed with carcinoma (34%) or skin
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melanoma (25%). The proportion of AYA cancer patients identified with at least
one subsequent pregnancy (.20 weeks) during the follow-up period was 24%.
Table 2 compares the characteristics at index delivery of females diagnosed with
AYA cancer with those of the group who had no cancer history. Distribution for
maternal age, year of delivery, parity and Aboriginal status were similar between
groups.
Adverse maternal and neonatal outcomes
Comparative obstetric and perinatal complications after multivariate adjustment
are reported in Table 3. Female survivors were nearly twice as likely to undergo
fertility treatment compared with the non-cancer comparison group (adjusted






CNS tumor 76 (4%)
Bone sarcoma 38 (2%)
Soft tissue sarcoma 95 (5%)

















Type of cancer treatment
Surgery alone 644 (34%)
Chemotherapy alone 208 (11%)
Chemoradiation therapy 170 (9%)
Radiation therapy alone 170 (9%)
Other 701 (37%)
doi:10.1371/journal.pone.0113292.t001
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relative risks, ARR 1.9, 95% Confidence Interval, CI 1.4–2.7). Females who had
been diagnosed with AYA cancer had a higher risk of threatened abortion (2.1,
1.5–2.7), Pre-eclampsia (1.4, 1.1–1.9), gestational diabetes (2.7, 2.1–3.6), Cesarean
delivery (2.6, 2.2–3.0), and were more likely to have a length of stay of longer than
5 days (3.0, 1.7–5.6) compared with the non-cancer group.
Females in the cancer cohort were more likely to deliver infants at ,37 weeks
gestation (1.7, 1.2–2.1) or weighing ,2500 grams (1.5, 1.2–2.1) relative to the
comparison group. Infants born to females in the cancer cohort had an increased
risk of resuscitation (1.7, 1.3–2.2), low Apgar score (,7) at 1 minute (2.8, 2.3–
3.6), and admission to special care unit (1.4, 1.1–1.8). The male: female ratios of
offspring were similar in the cancer cohort and comparison group. Intrauterine
Table 2. Maternal characteristics of females diagnosed with AYA cancer and a comparison group who had no cancer history.
Characteristic AYA cancer cohort, n (%) Comparison cohort, n (%)
Total 1894 (100%) 4138 (100%)
Maternal age at delivery (years)
15–19 193 (10%) 455 (11%)
20–29 841(44%) 1779 (43%)
30–34 550 (29%) 1242 (30%)
$35 310 (16%) 662 (16%)
Year of delivery
1982–1988 246 (13%) 497 (12%)
1989–1995 398 (21%) 828 (20%)
1996–2001 587 (31%) 1324 (32%)
2002–2007 663 (35%) 1489 (36%)
Parity
Para 1 1023 (54%) 2193(53%)
Para2 417 (22%) 952 (23%)
Para 3 or more 454 (24%) 993 (24%)
Indigenous status 57 (3%) 83 (2%)
Married/defacto status 1686 (89%) 3931 (95%)
Smoked during pregnancy 284 (15%) 455 (11%)
Genital herpes 47 (3%) 86 (2%)
Pre-existing diabetes 114 (6%) 207 (5%)
Asthma 190 (10%) 335 (8%
Previous cesarean section 152 (8%) 455 (11%)
Socioeconomic disadvantage
Low 587 (31%) 1366 (33%)
Mid 663 (35%) 1407 (34%)
High 644 (34%) 1366 (33%)
Residential remoteness 284 (15%) 952 (23%)
Insurance status
Private 1155 (61%) 1821 (44%)
Public 739 (39%) 2317 (56%)
doi:10.1371/journal.pone.0113292.t002
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and neonatal deaths and congenital abnormalities occurred in similar proportions
in both cohorts.
Outcomes by diagnostic and treatment categories
Tables 4 shows the risks (ARR) of adverse obstetric and neonatal complications
respectively, among females with previous cancer compared with those without,
according to AYA cancer diagnostic characteristics and treatment details. Risk of
all four obstetric outcomes was highest for older women (30–39 years) and in the
2002–2007 calendar period of diagnosis. All adverse outcomes were also most
likely after diagnosis of CNS tumor (except cesarean section) and carcinomas.
Table 3. Risk of maternal and perinatal adverse outcomes following births among females diagnosed with AYA cancer and comparison group.
AYA cancer Comparison ARR (95% CI) a
Maternal complications
Threatened abortion (,20 weeks) 76(4%) 83 (2%) 2.09 (1.51–2.74)
Threatened preterm labor (20–36 weeks) 54 (3%) 91 (2%) 1.28 (0.88–1.88)
Pre-eclampsia 69 (4%) 111 (3%) 1.44 (1.13–1.87)
Maternal anemia 21(1%) 39 (1%) 1.31 (0.71–2.19)
Gestational diabetes 101 (5%) 83 (2%) 1.38 (1.09–2.98)
Postpartum hemorrhage 95 (5%) 199 (5%) 1.08 (0.82–1.56)
Antepartum hemorrhage 17 (1%) 41 (1%) 0.92 (0.59–1.78)
PRoM 99 (5%) 207 (5%) 0.99 (0.83–1.31)
Failure to progress 32 (2%) 47 (1%) 1.51 (0.97–2.37)
Retained placenta 57 (3%) 128 (3%) 0.98 (0.73–1.34)
Cesarean delivery 342 (18%) 288 (7%) 2.62 (2.22–3.04)
Postpartum LOS.5 days 227 (12%) 189 (5%) 3.01 (1.72–5.58)
Use of fertility treatment 57 (3%) 42 (1%) 1.94 (1.36–2.69)
Perinatal complications
Sex ratio (reference: male) 948 (50%) 2029 (49%) 1.05 (0.98–1.10)
Gestational age at birth
20–36 weeks 284 (15%) 412 (10%) 1.68 (1.21–2.08)
37–40 weeks 1458 (77%) 3310 (80%) Reference
41–43 weeks 152 (8%) 416(10%) 1.04 (0.94–1.56)
Birth weight
,2500 g 246 (13%) 331 (8%) 1.51 (1.23–2.12)
2500–4000 g 1439 (76%) 3435(83%) Reference
.4000 g 208 (11%) 372 (9%) 1.33 (0.99–1.71)
Intrauterine growth restriction 119 (6%) 94 (2%) 1.21 (0.97–2.06)
Low Apgar score at 1 min (,7) 189 (10%) 124 (3%) 2.83 (2.28–3.56)
Resuscitation 164 (9%) 207 (5%) 1.66 (1.27–2.19)
Admission to special/intensive care 97(5%) 150 (4%) 1.44 (1.13–1.78)
Intrauterine death 38 (2%) 81 (2%) 1.07 (0.86–1.65)
Neonatal death 19 (1%) 41 (1%) 1.03 (0.54–1.71)
Congenital abnormalities 12 (1% 33 (1%) 0.78 (0.41–1.37)
doi:10.1371/journal.pone.0113292.t003
Adverse Pregnancy Outcomes after Adolescent and Young Adult Cancer
PLOS ONE | DOI:10.1371/journal.pone.0113292 December 8, 2014 7 / 16
Table 4. Selected adverse obstetric and perinatal outcomes according to AYA cancer characteristics and treatment details, Adjusted Relative Risk versus
non-cancer comparison group (95% CI)a.












Age at diagnosis (years)






1.34 (0.81–2.43) 1.13 (0.68–1.72)






2.24 (1.56–3.65) 1.35 (0.72–2.81)






1.81 (1.01–2.68) 1.68 (1.18–2.35)
Diagnosis period






1.48 (0.75–1.42) 0.98 (0.67–2.15)






1.31 (0.52–2.94) 0.92 (0.29–2.90)






2.44 (1.18–4.59) 1.16 (0.98–1.67)






1.56 (0.93–2.67) 1.34 (1.06–2.70)
Diagnostic type






1.51 (0.77–3.24) 0.83 (0.43–2.47)






1.04 (0.54–1.87) 1.48 (0.42–5.83)













1.43 (0.76–1.57) 1.15 (0.86–1.72)






1.09 (0.94–1.93) 0.96 (0.42–6.18)






2.64 (1.14–4.88) 1.07 (0.81–1.84)






1.77 (0.32–4.91) 0.86 (0.43–3.12)






1.41 (1.04–2.95) 1.67 (1.18–3.09)
Anatomical site






2.16 (0.98–3.94) 1.63 (1.22–2.34)






2.21 (1.09–3.40) 1.18 (0.72–2.09)
Treatment type






0.98 (0.34–5.64) 1.84 (1.19–4.54)






2.14 (1.13–3.96) 1.63 (0.94–2.72)






1.08 (0.83–1.72) 1.17 (0.96–1.62)






1.78 (1.11–3.04) 1.04 (0.55–2.29)
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Risk of cesarean section was high after bone carcinoma and the risk of maternal
diabetes was high following diagnosis of almost all of the cancer types. All adverse
outcomes were slightly more likely following a diagnosis of a cancer in the pelvis.
Risk of threatened abortion and pre-eclampsia were more likely following
radiation therapy alone rather than other treatment types, but maternal diabetes
was more likely after chemoradiation and cesarean section was most likely after
chemotherapy alone.
The risks of all adverse perinatal outcomes tend to risk with increasing age of
diagnosis. With the exception of low Apgar score, adverse perinatal outcomes
were mostly likely to occur in the most study periods. All adverse outcomes were
more likely in the offspring of females previously diagnosed with carcinomas. The
risk of preterm delivery and LBW, resuscitation were highest in the offspring of
survivors of leukemia. The risk of preterm delivery, LBW and resuscitation were
highest among offspring of women with malignancies arising in the pelvis. The
offspring of women exposed to radiation had a high risk of preterm delivery, LBW
and low Apgar score whereas resuscitation was most likely in women who were
exposed to chemotherapy.
No significant increases in risks for antepartum hemorrhage, postpartum
hemorrhage, IUGR, PRoM, failure to progress, retained placenta, intrauterine
death or neonatal death were observed across cancer diagnostic and treatment
categories (data not shown).
Discussion
Main findings
In this large study of pregnancy outcomes following AYA cancer, female survivors
had a moderately increased risk of obstetric complications such as threatened
abortion, cesarean delivery, pre-eclampsia and gestational diabetes, compared to
females with no history of cancer. The offspring of female survivors had a higher
risk of preterm birth and LBW, and measures of neonatal distress (low Apgar
score at one minute, need for resuscitation, and admission to a special care unit)
compared to the offspring of females from the non-cancer cohort.
Subgroup analyses according to AYA cancer diagnostic characteristics and
treatment details found that threatened miscarriage was higher in survivors of
Table 4. Cont.


















1.11 (0.74–1.61) 2.82 (0.37–12.8)
aThe final models were adjusted for: Aboriginal status, previous cesarean section, maternal smoking, use of fertility treatment, residential remoteness,
hospital status.
doi:10.1371/journal.pone.0113292.t004
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AYA cancer diagnosed at an older age, those with a history of CNS tumors and
carcinomas, abdominopelvic site tumors as well as females who had been treated
with radiotherapy. Generally speaking, the most important antecedent to
miscarriage is chromosomal abnormality [28]. Other factors which influence the
risk of miscarriage include older maternal age, congenital uterine abnormalities,
autoimmune factors, thrombophilic disorders, maternal endocrine abnormalities
(e.g., poorly controlled diabetes and polycystic ovarian syndrome) [29]. Although
it is plausible that conditions such as autoimmune or metabolic disorders may
occur secondarily to cancer or its treatment, the specific reasons for threatened
miscarriage in this group of females is still unclear. However, the increased risk of
threatened miscarriage among survivors of pelvic tumors and those who had been
treated with radiation raises the possibility that this outcome is an adverse effect of
prior uterine irradiation [30]. Overall, there was no strong indication that
threatened abortion varied by cancer type except among females diagnosed with
CNS tumors and carcinoma. The CNS finding suggests that radiation to the brain
may increase the likelihood of a miscarriage, possibly through impairment of the
hypothalamic-pituitary-ovarian-axis [31, 32].
We found that gestational diabetes featured more frequently among survivors
of CNS tumours, bone sarcoma and carcinomas and patients with tumours
arising in the abdominal pelvic region. Our study also found maternal diabetes
was more common in females exposed to chemoradiation. Possible associations
between maternal diabetes and cancer subgroup are largely understudied. A few
studies have reported that childhood cancer survivors whose treatment included
cranial [33, 34] and total body irradiation [35] were at risk of diabetes mellitus.
The sequelae from cancer therapies, such as chemotherapy and radiotherapy, may
potentially compromise health in several ways that could lead to decreased
immune functioning, cardiotoxic effects, and weight gain [32], which may in turn
contribute to secondary health problems such as cardiovascular disease and
diabetes.
Cesareans were more common in females diagnosed with cancer compared
with those with no history of cancer and in particular common in those females
exposed to chemotherapy or radiotherapy, and females diagnosed with leukemia,
bone cancer and primary cancers in the abdomen or pelvis. The combination of
psychological and obstetric considerations has probably led to the high frequency
of cesarean delivery in females diagnosed with cancer. Possible clinician- and
patient-dependent reasons for an increased rate of planned cesarean sections,
including concerns over medical malpractice, fear of birth trauma and the
potential risk to the child due to difficult vaginal delivery. However, this does not
necessarily explain the specific difference identified within the observed results
and therefore requires further in-depth investigations.
The excess risk of low birth weight and preterm delivery among females treated
by radiation therapy is likely related to the radiation dose to the uterus
irrespective of cancer type [36], but it is difficult to distinguish between treatment
effects and cancer type. Survivors of certain cancer sub-types (e.g., lymphoma, soft
tissue sarcoma and carcinomas) had an increased risk of preterm delivery and
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offspring with LBW. Previous investigators have hypothesized that radiation-
induced damage to abdominopelvic tissue, including vasculature, could interfere
with fetal growth by physical constraint of uterine volume or by restricting
vascular support to the pregnancy, leading to low birth weight or small for
gestational age [11, 19, 37]. Also, uterine fibrosis might affect cervical competence
or placentation which are both associated to preterm delivery [32, 38–42].
Overall the offspring of female survivors of cancer were more likely to
experience fetal distress. The Apgar score, which is assigned to virtually every
newborn, evaluates the clinical state of the newborns based on five physical signs
(heart rate, respiratory effort, reflex irritability, muscle tone and color) present
shortly after birth [43]. A higher risk of low Apgar score was observed among
offspring of females who had a history of germ cell tumors and carcinoma and
those exposed to radiation therapy or chemoradiation. A low Apgar score is a
marker of a suboptimal fetal environment. The mechanism underlying this
observation is, however, unclear.
It is worth noting that, the gender ratio of the offspring of the females in our
study was not significantly different from that of the comparison group. This is
reassuring because it suggests that there is no deficit of male infants among the
offspring of the female survivors, a finding that, were it present, would suggest
transmission of lethal X-linked mutations [44].
The finding that more female cancer patients used fertility treatment than the
non-cancer comparison group was not surprising. We were unable to further
investigate specific associations between cancer diagnosis and fertility due to lack
of detail information regarding treatment exposure. However, a number of past
studies have found that certain chemotherapy treatment regimens [45], especially
those including high-dose alkylating agents, can lead to infertility. Pelvic
irradiation can also adversely affect ovarian function, whereas cranial radiation
can impair the hypothalamic pituitary function and cause hypogonadism through
gonadotropin-releasing hormone (GnRH) deficiency [46] and total-body
irradiation in hematologic malignancies affects uterine volume [47]. Due to these
potentially serious long-term fertility consequences, female patients should be
informed of available methods of fertility pereservations before the initiation of
cancer-directed therapy. Currently, there are several possibilities to preserve future
fertility, including in vitro fertilization (IVF) and embryo cryopreservation,
ovarian tissue cryopreservation, unfertilized ova cryopreservation, and the
administration of a GnRH agonist [48–51].
Strengths and Limitations
This retrospective study used routinely collected statutory data for the entire
population of Western Australia, which provided a large sample size and
minimized incomplete case ascertainment and loss to follow-up between cancer
diagnosis and pregnancy. The MNS provided us with comprehensive data about
gestational, delivery, and infant outcomes of completed pregnancies, but excluded
pregnancies resulting in completed miscarriage (,20 weeks). Information from
Adverse Pregnancy Outcomes after Adolescent and Young Adult Cancer
PLOS ONE | DOI:10.1371/journal.pone.0113292 December 8, 2014 11 / 16
the registries included important confounders and well-established risk factors for
adverse outcomes, such as smoking. However, we did not have detailed
information about cancer therapies, such as radiation dose and field location or
specific chemotherapeutic agents. For example, lack of comprehensive treatment
information precluded investigating the risk of adverse pregnancy outcomes by
dose of radiation received to the reproductive organs; hence, residual confounding
by radiation exposure could have distorted the magnitude of the measured
associations. Furthermore, survivors included in this investigation were treated
between 1982 and 2007 and hence, less is known about the potential adverse
effects of more recent therapies which are believed to be much more aggressive
than earlier therapies. Survivors treated more recently are still relatively young and
the number of offspring born to these survivors will be relatively small. There are
inevitable caveats on interpretation of findings from subgroup analyses,
particularly as the routinely collected data in this study lacked certain important
clinical details, such that causal inferences are necessarily speculative. Further, we
lacked information about the patient’s childbearing intent, the number and
timing of attempts of post-treatment parenthood or whether assisted reproductive
technology was actually used because of patient or partners subfertility. Therefore
our findings are primarily relevant to females who have attempted parenthood
and were able to become pregnant. It is also worth noting that the recording of a
number of maternal conditions such as diabetes may be less sensitive, albeit highly
specific and that the differential monitoring of females with a cancer history could
have resulted in the increased identification of some prenatal conditions.
Past studies
There are number of previous reports of pregnancy outcomes in long-term
survivors of diverse types of pediatric cancer [10–20]. However, only a few
published studies have specifically focused on patients of childbearing age at the
time of cancer diagnosis [52–56]. Like our study, these studies reported
significantly elevated risks of preterm delivery and LBW, ranging from 1.3–3.1
[53, 56, 57] and 2.0–3.7 [56, 57], respectively. Two studies reported additionally
that infants born to female AYA cancer survivors were also at higher risk of
perinatal death [1.9–2.3] compared to offspring of females with no prior cancer
diagnosis [56, 57]. After adjustment for prematurity, another study found that the
risk of early death or stillbirth was not increased [54]. One study found that
cancer survivors had higher rates of postpartum hemorrhage (OR 1.56) and
operative or assisted delivery (OR 1.33) compared with females without a history
of cancer [55]. The principal limitations in these recent studies investigating
outcomes in AYA females arises from the fact that some past studies using
hospital based data from single institutions, which may have hindered accurate or
valid quantification of risks due to small sample size [57]; another study focused
exclusively on a few neonatal outcomes (preterm delivery, LBW) and did not
quantify maternal-related complications [53, 56]. Although one study extended
the age range of cancer survivors by including patients aged 0 to 43 years, they did
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not separately report diagnostic age-specific risk estimates for AYAs [55]. Our
study presents a detailed assessment of maternal outcomes in female survivors of
adolescent and young adult cancers.
Conclusions
Our data indicate that AYA cancer survivors who are have an excess risk of
threatened abortions, cesarean delivery, preeclampsia, diabetes and their offspring
have a moderately elevated risk of preterm birth and LBW. Our findings also
suggest an adverse association between older age at diagnosis, certain cancer
diagnoses and therapies, namely radiation therapy and cancer in the abdominal-
pelvic region. Although their infants may be more likely to be preterm or of low
birth weight, we observed no increases in congenital malformations, or neonatal
death and no altered male to female sex ratio that might indicate increased germ
cell mutagenicity. Overall, our results indicate a need for close surveillance of
female survivors of AYA cancers. Understanding the effects of cancer on future
childbearing may assist in the strategic targeting of resources to give these females
the best care and access to treatment.
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